Data from a trial of Keystone Heart‘s TriGuard anti-stroke device showed a lower rate of neurologic deficits after transcatheter aortic valve implantation, according to research presented last month at EuroPCR 2015 in Paris. The 85-patient Deflect 3 study found that TAVI patients treated with the Israeli company’s TriGuard, which is designed to allow blood to […]
The post TAVI: Good early data for Keystone Heart’s TriGuard appeared first on MassDevice.
from MassDevice http://ift.tt/1cvAFYS
Cap comentari:
Publica un comentari a l'entrada